Fig. 4: Predictive value of ctDNA variations on tebentafusp. | Nature Communications

Fig. 4: Predictive value of ctDNA variations on tebentafusp.

From: Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Fig. 4

According to variation at 12 weeks (A) 3 weeks (B) and 12 weeks in patients with progressive disease at first assessment (C). OS: overall survival. Clearance of ctDNA is defined as the absence of detectable ctDNA at 3 weeks or 12 weeks after treatment, following an initial detection of ctDNA at baseline. Kaplan–Meier plots were used for survival analysis, with significance assessed using the two-sided log-rank test. Source data are provided as a Source Data file.

Back to article page